Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Summary not available.
Summary not available.
Summary not available.
Clarivate Plc (NYSE:CLVT) released a report highlighting the impact of globalization on U.S. research, urging for continued investment and collaboration to sustain its position as a science leader. The analysis, drawn from the Institute for Scientific Information, points out that U.S. research growth has not kept pace with global counterparts, particularly in Asia and the EU. Key findings include a doubling of international collaboration, particularly with Mainland China, and a decline in the diversity of research subjects due to faster budget increases in biomedicine. Furthermore, research output is unevenly distributed across the U.S., necessitating focused funding in weaker areas. The report warns that the U.S. no longer dominates global research, with other nations producing increasingly impactful papers.
On April 26, 2023, Clarivate (NYSE: CLVT) announced the appointment of Henry Levy as President of its Life Sciences & Healthcare segment, effective May 1, 2023. Levy, formerly with Veeva Systems, possesses over 25 years of experience in the life sciences sector, having held prestigious roles focused on enhancing drug development and commercialization. CEO Jonathan Gear expressed confidence in Levy's ability to accelerate growth and innovation within the segment, which aims to connect clients with transformative intelligence and data technology. This appointment rounds out recent leadership changes, including Gordon Samson and Bar Veinstein as Presidents of Intellectual Property and Academia & Government, respectively.
Clarivate Plc (NYSE: CLVT) announced it will report its financial results for Q1 2023 on May 9, 2023, before the market opens. The earnings release and supplemental information will be available on the Clarivate investor website. A conference call and webcast to discuss the results will occur on the same day at 9:00 AM Eastern Time. Interested participants can access the live broadcast through the investor relations section or by dialing the provided numbers. This event reflects Clarivate's commitment to transparency in sharing vital business information.
For more details, including the conference call access numbers and links to the live webcast, please visit the company's investor relations page.
Clarivate Plc (NYSE: CLVT) has appointed Bar Veinstein as President of Academia & Government, effective April 24, 2023. Veinstein, who previously served as CEO of Taranis, brings extensive experience in AI and cloud technologies. His prior role as President of Ex Libris Group saw him expand its reach to over 7,500 institutions globally. This appointment positions Clarivate to enhance growth within its Academia & Government segment, aiming to support educational institutions in achieving research excellence. The announcement follows a similar appointment of Gordon Samson as President of Intellectual Property, indicating a strategic focus on leadership within key market segments.
Clarivate (NYSE: CLVT) announces a special series by BioWorld titled Radiopharmaceuticals: The next big disrupter, focusing on the emerging field of radiopharmaceutical therapy, projected to reach $12 billion by 2030. This eight-part series investigates new uses and alternatives in cancer treatment, highlighting the evolution from one therapy in the 1950s to a range of options today that deliver targeted radiation to tumors. Key topics include the challenges facing radiopharma stakeholders, the industry's growth potential, and regulatory hurdles. Lynn Yoffee, Publisher of BioWorld, emphasizes the rapid advancements and substantial investments, including $6 billion by Novartis AG. The series contributes valuable insights into the radiopharmaceutical pipeline and how these therapies could transform cancer treatment.
Clarivate Plc (NYSE: CLVT) announced the appointment of Gordon Samson as President of its Intellectual Property (IP) market segment, effective April 1, 2023. Previously serving as Chief Product Officer, Samson aims to drive growth in the IP sector. The company also nominated Dr. Saurabh Saha for election to the Board at the Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in pharmaceuticals and biotech. This strategic move is to enhance leadership as Clarivate executes its growth strategy in Life Sciences & Healthcare.
Clarivate Plc (NYSE: CLVT) has announced the appointment of Gordon Samson as President of its Intellectual Property market segment, effective April 1, 2023. This new role aims to enhance growth within the IP sector. Additionally, Dr. Saurabh Saha has been nominated for election as an Independent Director at the upcoming 2023 Annual General Meeting on May 4, 2023. Dr. Saha, currently CEO of Centessa Pharmaceuticals (NASDAQ: CNTA), brings extensive experience in the pharmaceutical and biotech fields. Clarivate's CEO, Jonathan Gear, expressed confidence in Samson's ability to drive innovation and growth.